ANCA-associated vasculitis

Navarro-Mendoza EP, Tobón GJ. Curr Rheumatol Rep 2018; 20: 23. doi: 10.1007/s11926-018-0736-2

Genga E, Oyoo O, Adebajo A. Curr Rheumatol Rep 2018; 20: 4. doi: 10.1007/s11926-018-0711-y

Suwanchote S et al. Clin Rheumatol 2018; Advance online publication. doi: 10.1007/s10067-018-4062-x

Felicetti M et al. Clin Rheumatol 2018; Advance online publication. doi: 10.1007/s10067-018-4019-0

A meta-analysis has highlighted the cardiovascular risk faced by patients with vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies.

A post-hoc analysis of combined trial data suggests that extending azathioprine maintenance therapy beyond 18 months is not necessary for preventing relapses among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.

Brogan & Eleftheriou summarize recent advances in the understanding of the pathophysiology of primary systemic vasculitides and the potential role of novel biomarkers discovered in that context. 

Brogan P, Eleftheriou D. Pediatr Nephrol 2017. doi:10.1007/s00467-017-3597-4

Kellett et al. summarize the recent literature on the pathogenesis, management, and outcome of small-, medium-, and large-vessel renal vasculitis in the pediatric population.

Kellett S, Jawa N, Noone D. Curr Pediatr Rep 2017;5:87-99. doi:10.1007/s40124-017-0138-3

The authors of this review describe the efficacy and safety of rituximab as a remission induction and maintenance therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Hassan RI & Gaffo AL. Curr Rheumatol Rep 2017;19:6. doi:10.1007/s11926-017-0632-1

This review discusses the clinicopathological classification systems that define antineutrophil cytoplasmic autoantibody-associated vasculitis, and how their specificity relates to therapy response and prognosis.

Nat Rev Rheumatol 2016;12:570–579. doi:10.1038/nrrheum.2016.123

The review discusses small vessel vasculitides, evaluating recent trial results and analysing medical tools recommended for treatment, bearing in mind the need for development of therapeutic guidelines.

Lopalco G et al. Curr Rheumatol Rep 2016;18:36. doi:10.1007/s11926-016-0580-1

This review focuses on the considerable recent therapeutic advances for the treatment of vasculitis, including the development of outcome measures facilitating clinical trial design.

Eleftheriou D & Brogan PA. Pediatr Rheumatol 2016;14:26. doi:10.1186/s12969-016-0082-8

Recognising that although epigenetic studies in vasculitis are still in their infancy, the authors review the most recent data on these mechanisms to better understand the pathogenesis of this disease.

Renauer P, Coit P, & Sawalha AH. Clinic Rev Allerg Immunol 2016;50:357. doi:10.1007/s12016-015-8495-6